Inclusion Criteria:

- Age ≥ 20 years;

- Histologically or cytologically proven advanced or metastatic solid tumor;

- Evidence of progressive disease after standard chemotherapy or no standard
chemotherapy;

- Confirmation of availability of formalin-fixed paraffin-embedded (FFPE) tumor
block(s) or tissue sections;

- Presence of at least one measurable lesion according to RECIST version 1.0. Complete
tumor assessment to be performed within the 30 days prior to the first EMD 525797
administration;

- ECOG performance status of 0 to 1;

- Estimated life expectancy of at least 3 months;

- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L;

- Platelets ≥ 100 x 109/L;

- Hemoglobin ≥ 9.0 g/dL (without transfusions);

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN);

- Aspartate transaminase (AST), alanine transaminase (ALT) ≤ 3 x ULN;

- In subjects with hepatic metastasis, total bilirubin ≤ 3 x UNL, AST and ALT ≤ 5 x
UNL;

- Prothrombin time (PT), prothrombin time/international normalized ratio (PT/INR), and
activated partial thromboplastin time (APTT) within normal limits;

- Creatinine clearance ≥ 50 mL/min

Exclusion Criteria:

- Previous treatment with anti-integrin therapy;

- Radiotherapy to bone lesions, systemic surgery, orthopedic surgery (all within the 4
week prior to treatment with EMD 525797), clinically significant unhealed wound, or
unrecovered bone fracture;

- Chronic doses of oral steroids, defined as ≥ 10 mg of prednisone equivalents per day;

- Confirmed or clinically suspected brain or leptomeningeal metastases;

- Known hypersensitivity to EMD 525797 or its excipients;

- History of allergic reactions to other monoclonal antibody therapy;

- Antibody treatment within the past 8 weeks or chemotherapy within the 4 weeks prior
to treatment with EMD 525797;

- Uncontrolled diabetes;

- Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or
diastolic blood pressure ≥ 100 mmHg under resting conditions;

- Autoimmune diseases;

- Current history of chronic daily acetylsalicylic acid (ASS) therapy (ASS at doses ≤
100 mg is permitted);

- Bleeding disorders;

- History of thromboembolic events (history of superficial thrombophlebitis is not an
exclusion

- Anticoagulants within the past 10 days prior to the first treatment and during
treatment period;

- Severe peripheral vascular disease or ulceration;

- Unstable angina pectoris, or myocardial infarction or other severe heart diseases
within the past 6 months before treatment with EMD 525797;

- Clinical significant abnormal ECG at screening;

- Dementia, altered mental status, or any psychiatric condition that would prohibit the
understanding or rendering of informed consent;

- Known HIV infection, active or chronic carrier of hepatitis B virus (HBV antigen
positive or HBV DNA positive) or hepatitis C virus (HCV antibody positive)